

Figure e-1. Changes in MxA mRNA expression from baseline (BL) to 3 months (3M) in the relapse responders and non-responders. P-values were determined using a paired t-test. The data represent the mean +/- standard error of the mean.




Figure e-2. Changes in MxA RNA expression from baseline (BL) to 3 months (3M) in the Expanded Disability Status Scale responders (Resp) and non-responders (Non-Resp). P-values were determined using a paired t-test. The data represent the mean +/- standard error of the mean.




Figure e-3. Cytokine concentrations of IL-1 β in all MS samples do not have a Gaussian distribution.




Figure e-4. Pretreatment concentrations of **(A)** CD40L, **(B)** G-CSF, **(C)** CXCL10/IP10 and **(D)** IL-6 in Group 4 vs Group 5. P-values were determined using a Mann Whitney U test.




Figure e-5. A) Duration of disease before initiating therapy and **B)** Baseline Expanded Disability Status Scale (EDSS) in patients in Group 2 (GR2) compared to all other patient groups. P-values were determined using a Mann Whitney test.




Figure e-6. Changes in MxA mRNA expression from baseline (BL) to 3 months (3M) in the patient groups defined by baseline cytokine profiles. P-values were determined using a paired t-test. The data represent the mean +/- standard error of the mean.